87.12
0.79%
0.68
After Hours:
91.47
4.35
+4.99%
Arcellx Inc stock is traded at $87.12, with a volume of 2.33M.
It is up +0.79% in the last 24 hours and up +11.36% over the past month.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
See More
Previous Close:
$86.44
Open:
$80.22
24h Volume:
2.33M
Relative Volume:
4.66
Market Cap:
$4.65B
Revenue:
$144.75M
Net Income/Loss:
$-53.89M
P/E Ratio:
-22.00
EPS:
-3.96
Net Cash Flow:
$-42.88M
1W Performance:
-0.15%
1M Performance:
+11.36%
6M Performance:
+65.34%
1Y Performance:
+95.21%
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-04-24 | Reiterated | Needham | Buy |
Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
Oct-30-23 | Initiated | TD Cowen | Outperform |
Oct-17-23 | Initiated | UBS | Buy |
May-18-23 | Initiated | Truist | Buy |
Apr-14-23 | Initiated | Robert W. Baird | Outperform |
Mar-14-23 | Initiated | Stifel | Buy |
Feb-13-23 | Initiated | H.C. Wainwright | Buy |
Dec-13-22 | Resumed | BofA Securities | Buy |
Oct-31-22 | Initiated | Guggenheim | Buy |
Oct-27-22 | Initiated | Needham | Buy |
Jul-20-22 | Initiated | Canaccord Genuity | Buy |
Mar-01-22 | Initiated | BofA Securities | Buy |
Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
BofA raises Arcellx price target to $100 on positive data - Investing.com
Arcellx (NASDAQ:ACLX) Shares Gap DownHere's Why - MarketBeat
Arcellx issues updates on anito-cel clinical trials (NASDAQ:ACLX) - Seeking Alpha
Mirae Asset Global Investments Co. Ltd. Acquires 347 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx : to Present Clinical Data for Its Phase 1 and iMMagine 1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine 3 Study Form 8 K - Marketscreener.com
Arcellx reports promising results for myeloma treatment - Investing.com
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study - Marketscreener.com
Arcellx's Multiple Myeloma Drug Shows 95% Response Rate in Phase 2 Trial, Strong Safety Data | ACLX Stock News - StockTitan
Cancer cell therapy from Arcellx, Gilead shows promise in early data - Yahoo Finance
Arcellx, Inc. (NASDAQ:ACLX) Shares Purchased by Harbor Capital Advisors Inc. - MarketBeat
abrdn plc Takes Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Arcellx (NASDAQ:ACLX) Earns “Buy” Rating from Needham & Company LLC - Defense World
Arcellx (ACLX) Surged in Q3. Here’s Why - Insider Monkey
Arcellx (NASDAQ:ACLX) Receives Buy Rating from Needham & Company LLC - MarketBeat
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 5.3% - MarketBeat
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Increases By 5.3% - Defense World
Arcellx shares target increased, Outperform upheld as ASH data release nears - Investing.com India
A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX) - Simply Wall St
Arcellx's SWOT analysis: cell therapy innovator's stock poised for growth By Investing.com - Investing.com Australia
Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores - STAT
Arcellx's SWOT analysis: cell therapy innovator's stock poised for growth - Investing.com India
Arcellx director Kavita Patel sells $134,535 in stock - Investing.com
Arcellx, Inc. (NASDAQ:ACLX) Director Sells $134,535.00 in Stock - MarketBeat
Arcellx director Kavita Patel sells $134,535 in stock By Investing.com - Investing.com Canada
Cracking The Code: Understanding Analyst Reviews For Arcellx - Benzinga
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Arcellx (NASDAQ:ACLX) Reaches New 52-Week High After Analyst Upgrade - Defense World
Arcellx (NASDAQ:ACLX) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Canaccord Genuity Group Increases Arcellx (NASDAQ:ACLX) Price Target to $115.00 - Defense World
Stifel Nicolaus Increases Arcellx (NASDAQ:ACLX) Price Target to $122.00 - Defense World
(ACLX) Trading Advice - Stock Traders Daily
Stifel lifts Arcellx stock target, keeps buy rating on safety profile optimism - Investing.com India
4 Analysts Assess Arcellx: What You Need To Know - Benzinga
Arcellx (NASDAQ:ACLX) PT Raised to $122.00 - MarketBeat
Stifel lifts Arcellx stock target, keeps buy rating on safety profile optimism By Investing.com - Investing.com South Africa
Arcellx (NASDAQ:ACLX) PT Raised to $115.00 at Canaccord Genuity Group - MarketBeat
Arcellx stock soars to all-time high of $88.67 amid robust growth - Investing.com Australia
Examining the Potential Price Growth of Arcellx Inc (ACLX) - Knox Daily
Arcellx (NASDAQ:ACLX) Reaches New 1-Year HighTime to Buy? - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Shares Acquired by AQR Capital Management LLC - Defense World
12,035 Shares in Arcellx, Inc. (NASDAQ:ACLX) Purchased by SG Americas Securities LLC - MarketBeat
Arcellx Inc (ACLX) may enjoy gains as insiders got busy in the recent days - Knox Daily
ACLX’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
(ACLX) Technical Data - Stock Traders Daily
Arcellx (NASDAQ:ACLX) Shares Gap UpHere's What Happened - MarketBeat
Redburn sees Arcellx stock gaining from innovative CAR-T platform and strong growth - Investing.com Canada
The Manufacturers Life Insurance Company Increases Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx (NASDAQ:ACLX) Earns Buy Rating from Analysts at Redburn Atlantic - MarketBeat
The Manufacturers Life Insurance Company Boosts Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):